Analogs of cocaine

A compound of formula I:

• wherein
• Y is —C(R4)(R5)—;
• R1 is —C(═O)ORa,
• R2 is hydrogen or (C1 -C6)alkyl;
• R3 is 4-chlorophenyl, 4-fhluorophenyl, 4-methylphenyl, or 4-isopropenylphenyl;
• R4 and R5 are independently hydrogen or (C1-C6)alkyl;
• R4 is hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, or S(O)2Rh;
• n is 0, 1 or 2;
• Ra to Rg are independently hydrogen or (C1-C4)alkyl;
• and
• Rh is H, (C1-C4)alkyl, or phenyl;
• or a pharmaceutically acceptable salt thereof.

A compound of formula I:

• wherein
• Y is —C(R4)R5);
• R1 is (C1-C6)alkyl, wherein (C1-C6)alkyl, may optionally be substituted by 1, 2 or 3 Z, wherein each Z is independently halo, nitro, cyano, hydroxy, (C1-C6)alkoxy, (C2-C6)acyloxy, C(═O)ORb, C(═O)NRcRd, NReRf or S(═O)nRg;
• and R3 is (C6-C10)aryl, wherein said aryl substituent may optionally be substituted on carbon by 1, 2 or 3 Z;
• R2 is hydrogen or (C1-C6)alkyl;
• R4 and R5 are independently hydrogen or (C1-C6)alkyl;
• R6 is hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, or S(O)2Rh;
• n is 0, 1 or 2,
• Ra to Rg are independently hydrogen or (C1-C4)alkyl;
• and
• Rh is H, (C1-C4)alkyl, or phenyl;
• or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition, comprising a therapeutically effective amount of a compound of formula I:

• wherein
• Y is —C(R4)(R5)—;
• R1 is —C(═O)ORa, cyano, (C1-C6)alkyl, (C1-C6)alkanoyl, (C1-C6)alkenyl, (C2-C6)alkynyl, or 1, 2, 4-oxadiazol-5-yl optionally substituted at the 3-position by W, wherein any (C1-C6)alkyl, (C1-C6)alkanoyl, (C2-C6)alkenyl, or (C2-C6)alkynyl may optionally be substituted by 1, 2 or 3 Z, wherein each Z is independently halo, nitro, cyano, hydroxy, (C1-C6)alkoxy, (C2-C6)acyloxy, C(═O)ORb, C(═O)NRcRd, NReRf, or S(═O)nRg;
• and R3 is 5-10 membered heteroaryl, (C6-C10)aryl(C1-C6)alkyl, 5-10 membered heteroaryl(C1-C6)alkyl, (C6-C10)arylcarbonyl, or 5-10 membered heteroarycarbonyl, wherein any aryl or heteroaryl substituent may optionally be substituted on carbon by 1, 2 or 3 Z
• R2 is hydrogen or (C1-C6)alkyl;
• R4 and R5 are independently hydrogen or (C-C6)alkyl;
• R6 is hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, or S(O)2Rh;
• n is 0, 1 or 2;
• W is (C1-C6)alkyl, or phenyl, optionally substituted by 1, 2, or 3 Z;
• Ra to Rg are independently hydrogen or (C1-C4)alkyl;
• and
• Rh is H, (C1-C4)alkyl, or phenyl;
• or a pharmaceutically acceptable salt thereof;
• and
• a pharmaceutically acceptable diluent or carrier.

A pharmaceutical composition, composition, a therapeutically effective amount of a compound of formula I:

• wherein
• Y is —C(R4)(R5)—;
• R1 is —C(═O)ORa;
• R2 is hydrogen or (C1-C6)alkyl;
• R3 is 4-chlorophenyl, 4-fluorophenyl, 4-methylphenyl, or 4-isopropenyephenyl;
• R4 and R5 are independently hydrogen or (C1-C6)alkyl;
• R6 is hydrogen, (C1 -C6)alkyl, (C1-C6)alkanoyl, or S(O)2Rh;
• n is 0, 1 or 2;
• Ra to Rg are independently hydrogen or (C1-C4)alkyl;
• and
• Rh is H, (C1-C4)alkyl, or phenyl;
• or a pharmaceutically acceptable salt thereof;
• and
• a pharmaceutically acceptable diluent or carrier.

A pharmaceutical composition, comprising a therapeutically effective amount of a compound of formula I:

• wherein
• Y is —C(R4)(R5);
• R 1 is (C1-C6)alkyl, wherein (C1-C6)alkyl may optionally be substituted by 1, 2 or 3 Z, wherein each Z is independently halo, nitro, cyano, hydroxy, (C1-C6)alkoxy, (C2 -C6)acyloxy, C(═O)ORb, C(═O)NRcRd, NReRf, or S(═O)nRg;
• and R3 is (C6-C10)aryl, wherein said aryl substituent may optionally be substituted on carbon by 1, 2 or 3 Z;
• R3 is hydrogen or (C1-C6)alkyl;
• R4 and R5 are independently hydrogen or (C1-C6)alkyl;
• R6 is hydrogen, (C1-C6)alkyl, (C1-C4)alkanoyl, or S(O)2Rh;
• n is 0, 1 or 2;
• Ra to Rg are independently hydrogen or (C1-C4)alkyl;
• and
• Rh is H, (C1-C4)alkyl, or phenyl;
• or a pharmaceutically acceptable salt thereof;
• and
• a pharmaceutically acceptable diluent or carrier.